Biotechnology and scientific research in aging

Recent scientific and biotechnological developments are exploring methods to modulate or reverse biological aging processes.

In biotechnology, advancements include the development of rentosertib, an AI-designed drug from Insilico Medicine that has shown potential to reduce biological age by approximately three to four years according to proteomic aging clocks. Additionally, Epirium Bio is moving the MF-300 molecule into Phase 2 human testing. This drug targets “gerozymes,” specifically the enzyme 15-PGDH, to promote tissue repair and address age-related degeneration in muscles, joints, bones, and the brain.

Complementary research at the Icahn School of Medicine at Mount Sinai has demonstrated that inhibiting excessive lysosomal activity in aged hematopoietic stem cells can restore their regenerative power and mitochondrial performance. Meanwhile, neurobiological studies from the University of Arizona suggest that the aging brain undergoes a strategic reorganization, shifting control from the hippocampus to the prefrontal cortex to maintain complex reasoning and decision-making capabilities.